The $400 Billion Gamble: Why AstraZeneca's Mergers and Acquisitions Obsession Might Be a Recipe for Disaster A proposed merger between AstraZeneca and Bristol Myers Squibb has sent shockwaves through the pharmaceutical industry, with shares in both companies plummeting by as much as 7% on Monday morning.
The deal, valued at around $400 billion, has raised questions about whether such a massive marriage is in the best interests of either company.
AstraZeneca's leadership, under Pascal Soriot since 2012, has been aggressively pursuing mergers and acquisitions.